AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03480893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laminectomy
Description: A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.
Study NCT02122497 — intervention group
Intervention type: PROCEDURE
Intervention: abdominal aortic surgery
Study NCT02217514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 low dose
Study NCT02881840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-APD421
Study NCT01971970 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.
Study NCT01971970 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
Study NCT02728609 — intervention group
Intervention type: DEVICE
Intervention: ABThera vacuum device
Description: This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
Study NCT02092896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
Study NCT02092896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
Study NCT02092896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
Study NCT02092896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
Study NCT00175188 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avanta (PIP joint implant with a titanium porous coating)
Description: Implant is inserted at the time of surgery, after written consent
Study NCT03551496 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent - Below the Knee
Description: Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm
Study NCT03551496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA Control Arm
Description: The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
Study NCT02728609 — intervention group
Intervention type: DEVICE
Intervention: Blue towel: vacuum pack device
Description: This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
Study NCT01309594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
Study NCT02955602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025 2 mg Capsule
Description: Initial 8-week treatment:~• MBX-8025 2 mg~Extension:~The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.
Study NCT02955602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025 5 mg Capsule
Description: Initial 8-week treatment:~• MBX-8025 5 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.
Study NCT03983083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
Study NCT01471119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae Drops Group 1
Description: Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
Study NCT01471119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae Drops Group 2
Description: Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
Study NCT01471119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae Drops Group 3
Description: Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
Study NCT01471119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Group is the group with maintenance dose of 3 drops of placebo.
Study NCT02605993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: All treatments were given as IV infusions.
Study NCT04018612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen is an analgesic and antipyretic
Study NCT04018612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT01754285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LF-PB and Placebo
Study NCT04741841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GutMagnific™ H.
Description: Vegan Capsules with active product, GutMagnific™ high dose
Study NCT01754285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01754285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LF-PB
Study NCT02955602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025 10 mg Capsule
Description: Initial 8-week treatment:~• MBX-8025 10 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.
Study NCT04032860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil
Description: patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery
Study NCT04032860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery
Study NCT04741841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GutMagnific™ L.
Description: Vegan Capsules with active product, GutMagnific™ low dose
Study NCT04741841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vegan capsules identical to active product in taste and appearance but without probiotic
Study NCT03836846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT Mobile App
Description: TAU and the additional treatment of a Mental Health App (What's Up?). This app will be used to guide adolescents through cognitive behavioral therapy and acceptance commitment therapy techniques, as well as to assist in developing coping mechanisms to prevent readmission.
Study NCT03836846 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: TAU as per standard of care
Study NCT00657137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricoxib + lapatinib + capecitabine
Description: apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert
Study NCT00657137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + lapatinib + capecitabine
Description: placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert
Study NCT01474785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human ghrelin
Description: 0.5-1 pmol/kg.min of human ghrelin administered by IV two times
Study NCT01474785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low calorie diet
Description: standard very low calorie diet that is prescribed for all RYGB patients after their operation
Study NCT01474785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic/Euglycemic Clamp
Description: Insulin and glucose infusions to measure glucose kinetics.
Study NCT01552512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutributter Program
Description: Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
Study NCT01552512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Package
Description: The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
Study NCT02310737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sharp incision
Description: The fascia will be opened with a sharp scissors in cesarean section
Study NCT02310737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blunt incision
Description: Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
Study NCT01565408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0006
Description: Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
Study NCT01565408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
Study NCT03167788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rejuvesol Solution
Description: The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
Study NCT03167788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood \& Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
Study NCT04364815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine plus standard preventive measures
Description: Hydroxychloroquine and standard preventive measures
Study NCT04364815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard preventive measures
Description: Placebo tablet plus standard preventive measures as defined by PGH-HICU
Study NCT03542266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486 Administration
Description: CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
Study NCT03542266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP Administration
Description: CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5
Study NCT01637584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
Study NCT01637584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
Study NCT02827344 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample collection for CTC and MDSC analysis
Description: * Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~* Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~* Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry
Study NCT02200926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loaded breathing training
Description: 7 days/weeks, for 8 weeks
Study NCT02200926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unloaded breathing training
Description: 7 days/week, for 8 weeks
Study NCT02200926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 7 days/week, for 8 weeks
Study NCT00844831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg bid for 28 days
Study NCT03821155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: Specialized physical therapy aimed at restoring balance
Study NCT03821155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Prednisolone
Study NCT03821155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Prednisolone
Study NCT02366923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.
Study NCT02366923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.
Study NCT00870441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral
Study NCT00870441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Oral
Study NCT00870441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT00395304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + montelukast
Description: Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
Study NCT03636880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief treatment for Insomnia
Description: This behavioral intervention provides participants with an individualized plan to modify sleep patterns contributing to insomnia, as well as education about sleep hygiene and habits that help and hurt sleep.
Study NCT02366923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.
Study NCT02366923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.
Study NCT01183429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3F8 and 13-cis-retinoic acid
Description: 3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. \*High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
Study NCT03823105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OHR Tracker and PulseWatch
Description: Category A (ClinO). Medical study with CE-marked medical devices to photoplethysmographic measure heart rate, heart rate variability, and pulse wave and accelerometric data
Study NCT03981744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 6 mg/kg
Description: Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
Study NCT03981744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab 6 mg/kg
Description: Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
Study NCT03981744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
Study NCT03981744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab 90 mg
Description: Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
Study NCT03981744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
Study NCT03981744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
Study NCT03981744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
Study NCT03329625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways Triple P
Description: Pathways Triple was developed by Matt Sanders and is a behavioral parent training intervention designed to treat child behavior problems and prevent child maltreatment.
Study NCT03329625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Families received family centered services and other parenting interventions as deemed appropriate by the child welfare case manager.
Study NCT02936869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance-based monetary incentives